Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set

Emre Oto¹, Sercan Okutucu²*, Deniz Katircioglu-Öztürk¹, Halil Altay Güvenir³, Ergun Karaagaoglu⁴, Martin Borggreve⁵, Günter Breithardt⁶,⁷, Andreas Goette⁶,⁸, Ursula Ravens⁹, Gerhard Steinbeck¹⁰, Karl Wegscheider¹¹, Ali Oto², and Paulus Kirchhof⁶,¹²,¹³

¹Medical Information Technology Solutions (MITS), Bilkent University Cyberpark, Ankara, Turkey; ²Department of Cardiology, Memorial Ankara Hospital, Memorial Healthcare Group, Ankara, Turkey; ³Department of Computer Engineering, Faculty of Engineering, Bilkent University, Ankara, Turkey; ⁴Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey; ⁵Department of Cardiology, University of Mannheim, Mannheim, Germany; ⁶Atrial Fibrillation Network Association, Münster, Germany; ⁷Department of Cardiovascular Medicine, Division of Rhythmology, University Hospital Münster, Münster, Germany; ⁸Department of Cardiology, Vincenz-Krankenhaus, Paderborn, Germany; ⁹Department of Pharmacology, Technical University, Dresden, Germany; ¹⁰Department of Cardiology, Ludwig-Maximilians-University of Munich, Germany; ¹¹Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¹²Institute of Cardiovascular Sciences, University of Birmingham and SWBH and UHB NHS Trusts, Birmingham, UK; and ¹³Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany

Received 4 February 2016; accepted after revision 27 April 2016

Aims

Data mining is the computational process to obtain information from a data set and transform it for further use. Herein, through data mining with supportive statistical analyses, we identified and consolidated variables of the Flecainide Short-Long (Flec-SL—AFNET 3) trial dataset that are associated with the primary outcome of the trial, recurrence of persistent atrial fibrillation (AF) or death.

Methods and results

The ‘Ranking Instances by Maximizing the Area under the ROC Curve’ (RIMARC) algorithm was applied to build a classifier that can predict the primary outcome by using variables in the Flec-SL dataset. The primary outcome was time to persistent AF or death. The RIMARC algorithm calculated the predictive weights of each variable in the Flec-SL dataset for the primary outcome. Among the initial 21 parameters, 6 variables were identified by the RIMARC algorithm. In univariate Cox regression analysis of these variables, increased heart rate during AF and successful pharmacological conversion (PC) to sinus rhythm (SR) were found to be significant predictors. Multivariate Cox regression analysis revealed successful PC as the single relevant predictor of SR maintenance. The primary outcome risk was 3.14 times (95% CI:1.7–5.81) lower in those who had successful PC to SR than those who needed electrical cardioversion.

Conclusions

Pharmacological conversion of persistent AF with flecainide without the need for electrical cardioversion is a powerful and independent predictor of maintenance of SR. A strategy of flecainide pretreatment for 48 h prior to planned electrical cardioversion may be a useful planning of a strategy of long-term rhythm control.

Keywords

Atrial fibrillation ● Cardioversion ● Data mining ● Flecainide ● RIMARC algorithm

Introduction

Cardioversion of persistent and long-standing persistent atrial fibrillation (AF) is a common intervention in patients who are in need for rhythm control therapy. While this procedure restores sinus rhythm (SR) very effectively in the acute setting,⁴ long-term recurrences of AF are common after cardioversion.⁵,⁶ Identifying patients who are more likely to maintain SR for a longer time would help develop a personalized planning of rhythm control therapy. Unfortunately, such parameters are not well described.⁴

Data mining is the computational process of discovering patterns in large datasets involving methods at the intersection of artificial...
patients were adults with persistent AF undergoing planned cardioversion. All patients received 48 h or more of treatment with the study drug flecainide before planned electrical cardioversion. This was a mandatory part of the protocol meant to ensure effective flecainide plasma levels at the time of cardioversion. After successful cardioversion, patients were randomly assigned in permuted blocks of six per center to: no antiarrhythmic drug treatment (control), treatment with flecainide for 4 weeks (short-term treatment) or flecainide for 6 months (long-term treatment). The primary outcome was time to persistent AF or death.2

Data mining with RIMARC algorithm

The major aim of pursuing a data mining experiment on the Flec-SL dataset was to extract clinically relevant information. As in almost all widely used data mining techniques, the main objective was to reveal underlying patterns in a data set and generate hypotheses over them, rather than describing the nature of the data and demonstrate the significance of a model that relates the data instances to the underlying population as conventional statistical methods mostly do. Data Mining employs such techniques as linear and non-linear classification, clustering and association algorithms to identify trends to be fed into further analyses.5–7 With this goal of using data mining for hypothesis and model generation, a supervised model based on the RIMARC (Ranking Instances by Maximizing the Area Under a ROC Curve) classification algorithm5 was constructed. In this scope, RIMARC algorithm was used to assign ‘predictive weights’, \( w \in [0, 1] \), to each of the baseline clinical parameter in the Flec-SL data set for addressing the ‘class label’ denoting whether a patient reaches the primary outcome or not.

Briefly, the RIMARC algorithm has been proven5 to constitute a ranking function that attains the maximal area under the ROC curve (AUC) for a given set of input parameters. The classification model learned by the RIMARC algorithm can be used to estimate the likelihood, \( \text{score}(q) \), of reaching the primary endpoint for any new patient \( q \) as follows:

\[
\text{score}(q) = \frac{\sum q \in \mathcal{W}_q \, s_q(q)}{\sum q \in \mathcal{W}_q},
\]

where \( \mathcal{W}_q \) represents the weight of the clinical parameter (feature) \( q \), \( s_q \) is the value of the parameter (feature) \( f \) for patient \( q \), and \( s_{\text{missing}}(q) \) is the score associated with the value of the feature \( f \) for patient \( q \).5,6 RIMARC algorithm had been implemented as a proprietary suite in Java programming language and the source codes with executables are available upon request.

Statistical analysis

We used the RIMARC algorithm to individually identify the predictive power of parameters in predicting the primary outcome of the trial. For this analysis, we have only included the parameters that were collected at baseline and are biologically homogeneous. Full list can be seen in Table 1. As the univariate classifier for each parameter is built by RIMARC, the prediction accuracy of the calculated predictive weights (\( \mathbf{w} \)) are assessed in terms of AUC and their significances are validated by the widely used 10-fold cross-validation technique. In 10-fold cross-validation, the original sample is randomly partitioned into 10 equal size subsamples. Of the 10 subsamples, a single subsample is retained as the validation data for testing the model, and the remaining 9 subsamples are used as training data. The cross-validation process is then repeated 10 times (number of folds), with each of the 10 subsamples used exactly once as the validation data. The resulting risk classification was later used to calculate the AUC and the 95% CI corresponding to this AUC value.

Methods

Study design and participants

Between May 2007 and March 2010, 635 patients scheduled for planned electrical cardioversion were enrolled into a prospective, randomized, open-label, blinded endpoint assessment trial.5 Details of the trial design and the primary outcome have been reported previously.7 Eligible intelligence, machine learning, statistics, and database systems. The overall goal of the data mining process is to extract information from a data set and transform it into an understandable structure for further use.5–7 Aside from the raw analysis step, it involves database and data management aspects, data pre-processing, model and inference considerations, interestingness metrics, complexity considerations, post-processing of discovered structures, visualization, and online updating.5–7

The Flecainide Short-Long (Flec-SL—AFNET 3) trial2,8 is a prospective, randomised, open-label, blinded endpoint assessment trial that evaluated whether short-term antiarrhythmic drug treatment was non-inferior to standard long-term treatment to prevent recurrence of persistent AF after cardioversion. This trial revealed that short-term antiarrhythmic drug treatment after cardioversion was non-inferior to long-term treatment in a cohort of patients in whom electrical remodelling was thought to play a large part in recurrent AF.2 Additionally, the study confirmed that flecainide was effective in the prevention of recurrent AF after cardioversion.

Here, we applied machine learning to determine predictors of long-term maintenance of SR in the Flec-SL—AFNET 3 data set. We used the RIMARC (Ranking Instances by Maximizing the Area under the ROC Curve) classification algorithm.5,6 This algorithm operates by ranking instances based on how likely they are to have a positive label indicating the presence of a condition.7 By means of this type of data mining analysis, we tried to extract clinically relevant statistical information from the Flec-SL—AFNET 3 database and seek for factors that might affect recurrence of persistent AF after cardioversion, the primary outcome of the trial. We then applied validation by biostatistical analysis.

What’s new?

- Data mining is a novel computational process to obtain information from a data set and transform it for further use.
- In current study, through data mining with supportive statistical analyses, we identified and consolidated variables of the Flecainide Short-Long trial dataset that are associated with the primary outcome of the trial, recurrence of persistent atrial fibrillation or death.
- Pharmacological conversion of persistent AF with flecainide without the need for electrical cardioversion is a powerful and independent predictor of maintenance of sinus rhythm.
- A strategy of flecainide pretreatment for 48 h prior to planned electrical cardioversion may be a useful planning of a strategy of long-term rhythm control.
### Table 1  List of input variables in the order of their weights calculated by RIMARC and corresponding AUC values with p-values less than the significance level, \( \alpha = 0.05 \), are marked

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Weight (w)</th>
<th>AUC (RIMARC)</th>
<th>Weight (10-fold cross-validation)</th>
<th>Weight 95% CI LB (10-fold cross-validation)</th>
<th>Weight 95% CI UB (10-fold cross-validation)</th>
<th>AUC (10-fold cross-validation)</th>
<th>AUC 95% CI LB (10-fold cross-validation)</th>
<th>AUC 95% CI UB (10-fold cross-validation)</th>
<th>Significance for CI 95% (( \alpha = 0.05 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.215</td>
<td>0.607</td>
<td>0.074</td>
<td>-0.016</td>
<td>0.164</td>
<td>0.537</td>
<td>0.492</td>
<td>0.582</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Heart rate</td>
<td>0.193</td>
<td>0.597</td>
<td>0.126</td>
<td>0.036</td>
<td>0.216</td>
<td>0.563</td>
<td>0.518</td>
<td>0.608</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>PC upon flecainide pretreatment</td>
<td>0.181</td>
<td>0.590</td>
<td>0.184</td>
<td>0.096</td>
<td>0.274</td>
<td>0.592</td>
<td>0.548</td>
<td>0.637</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>SF-12, mental component, baseline</td>
<td>0.178</td>
<td>0.589</td>
<td>0.100</td>
<td>0.012</td>
<td>0.19</td>
<td>0.550</td>
<td>0.506</td>
<td>0.595</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>Left atrial diameter</td>
<td>0.162</td>
<td>0.581</td>
<td>0.042</td>
<td>-0.048</td>
<td>0.132</td>
<td>0.521</td>
<td>0.476</td>
<td>0.566</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>QRS duration</td>
<td>0.160</td>
<td>0.580</td>
<td>0.078</td>
<td>-0.012</td>
<td>0.168</td>
<td>0.539</td>
<td>0.494</td>
<td>0.584</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>BMI</td>
<td>0.138</td>
<td>0.569</td>
<td>0.140</td>
<td>0.050</td>
<td>0.228</td>
<td>0.570</td>
<td>0.525</td>
<td>0.614</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>SF-12, physical component, baseline</td>
<td>0.138</td>
<td>0.569</td>
<td>0.092</td>
<td>0.002</td>
<td>0.182</td>
<td>0.546</td>
<td>0.501</td>
<td>0.591</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>Total flecainide dose until cardioversion</td>
<td>0.126</td>
<td>0.563</td>
<td>0.018</td>
<td>-0.072</td>
<td>0.108</td>
<td>0.509</td>
<td>0.464</td>
<td>0.554</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Weight</td>
<td>0.125</td>
<td>0.563</td>
<td>0.048</td>
<td>-0.042</td>
<td>0.140</td>
<td>0.524</td>
<td>0.479</td>
<td>0.570</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>PR interval</td>
<td>0.122</td>
<td>0.561</td>
<td>0.046</td>
<td>-0.044</td>
<td>0.136</td>
<td>0.523</td>
<td>0.478</td>
<td>0.568</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.121</td>
<td>0.561</td>
<td>0.008</td>
<td>-0.082</td>
<td>0.098</td>
<td>0.504</td>
<td>0.459</td>
<td>0.549</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>0.120</td>
<td>0.560</td>
<td>0.128</td>
<td>0.038</td>
<td>0.218</td>
<td>0.564</td>
<td>0.519</td>
<td>0.609</td>
<td>( p &lt; \alpha )</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>0.105</td>
<td>0.553</td>
<td>0.052</td>
<td>-0.038</td>
<td>0.142</td>
<td>0.526</td>
<td>0.481</td>
<td>0.571</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Height</td>
<td>0.087</td>
<td>0.543</td>
<td>0.008</td>
<td>-0.082</td>
<td>0.098</td>
<td>0.504</td>
<td>0.459</td>
<td>0.549</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Use of oral anticoagulants</td>
<td>0.073</td>
<td>0.537</td>
<td>0.074</td>
<td>-0.018</td>
<td>0.164</td>
<td>0.537</td>
<td>0.491</td>
<td>0.582</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>CHADS2 score</td>
<td>0.060</td>
<td>0.530</td>
<td>0.040</td>
<td>-0.050</td>
<td>0.132</td>
<td>0.520</td>
<td>0.475</td>
<td>0.566</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Karnofsky index</td>
<td>0.060</td>
<td>0.530</td>
<td>0.032</td>
<td>-0.058</td>
<td>0.124</td>
<td>0.516</td>
<td>0.471</td>
<td>0.562</td>
<td>( p &gt; \alpha )</td>
</tr>
<tr>
<td>Diastolic posterior wall thickness</td>
<td>0.058</td>
<td>0.529</td>
<td>0.078</td>
<td>-0.012</td>
<td>0.168</td>
<td>0.539</td>
<td>0.494</td>
<td>0.584</td>
<td>( p &gt; \alpha )</td>
</tr>
</tbody>
</table>
These intervals, here, provide the range in which the true AUC value lies with CI 95%, indicating a significance level ($\alpha$) of 0.05. To assess the significance of AUC values found, one must point out the corresponding confidence intervals that do not embrace the null hypothesis of AUC being 0.500, that is the random classifier. If the null hypothesis is 'embraced' in any of the confidence intervals, then it is certainly not rejected therein, the $p$-value must be greater than the significance level ($\alpha$) of 0.05. On the other hand, if the 95% CI excludes the AUC value of 0.500, then the null hypothesis is said to be rejected, therefore, the $p$-value must be less than the significance level ($\alpha$) 0.05 which indicates a statistical significance.

This technique is useful when there is no separate test data set is available for validation, which is usually the case in the clinical domain. The factors that were determined to have a statistically significant predictive power via RIMARC were subject to univariate Cox regression analysis, and were integrated into a multivariate Cox model using Stata data analysis software version 13.1.

**Results**

**Variable selection and RIMARC-based classifiers**

By means of RIMARC algorithm, we obtained the predictive weights ($w$) together with the AUC values of each baseline parameter associated with recurrence of AF in other publications. After applying 10-fold cross-validation on the AUC values produced for each parameter, mean AUC’s with 95% confidence intervals are calculated. Among the initial 21 parameters, 6 variables were identified by the RIMARC algorithm. These variables were heart rate, PC upon flecainide pretreatment, body mass index, left ventricular ejection fraction, baseline SF-12 physical, and mental component scores which indicated as having significant AUC values in determining the primary outcome (Table 1).

**Univariate and multivariate analysis**

The 6 parameters at baseline determined also to have a statistically significant discrimination power via RIMARC were subject to univariate Cox regression analysis and were then used to build a multivariate Cox model. Increased heart rate during AF and PC upon flecainide pretreatment were found to be the significant predictors (significance level, $\alpha = 0.05$) in univariate Cox regression analysis.

The results of these analyses are presented in Table 2. It can be seen that the parameter of pharmacological conversion (PC) upon flecainide pretreatment is the single most relevant predictor of SR maintenance in multivariate Cox regression analysis. The results of these analyses are presented in Table 3. Multivariate Cox regression indicates that successful PC reduced the primary outcome risk by 3.14 times [95% CI: 1.7–5.81] than those with need for electrical cardioversion (hazard ratio: 0.318 [95% CI: 0.172–0.588]; $P < \alpha = 0.05$).

As illustrated in Figure 1, the Flec-SL dataset also shows that while 51% of patients who need electrical cardioversion reach the primary endpoint, this proportion is 23% in those patients who undergo successful PC. Therefore, the dataset also indicates that patients who undergo successful PC are 2.22 ($P < \alpha = 0.05$) times less likely to reach the primary endpoint than those patients who need electrical cardioversion.

---

**Table 1** Continued

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Weight ($w$)</th>
<th>AUC (RIMARC)</th>
<th>Weight 95% CI LB (10-fold cross-validation)</th>
<th>Weight 95% CI UB (10-fold cross-validation)</th>
<th>AUC (10-fold cross-validation)</th>
<th>AUC 95% CI LB (10-fold cross-validation)</th>
<th>AUC 95% CI UB (10-fold cross-validation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of beta blockers prior to cardioversion</td>
<td>0.007</td>
<td>0.529</td>
<td>0.024</td>
<td>0.512</td>
<td>0.024</td>
<td>0.512</td>
<td>0.024</td>
</tr>
<tr>
<td>Female gender</td>
<td>0.024</td>
<td>0.512</td>
<td>0.024</td>
<td>0.512</td>
<td>0.024</td>
<td>0.512</td>
<td>0.024</td>
</tr>
</tbody>
</table>

*Weight and AUC (RIMARC) refer to the predictive weights and corresponding area under the ROC curve values calculated by the algorithm when the whole dataset is used, while AUC (10-fold x-validation) refer to the lower and upper bounds of the weight that corresponds to the pertaining AUC values calculated through 10-fold cross-validation. BMI, body mass index; PC, pharmacological cardioversion.

---

The technique is useful when there is no separate test data set is available for validation, which is usually the case in the clinical domain. The factors that were determined to have a statistically significant predictive power via RIMARC were subject to univariate Cox regression analysis, and were integrated into a multivariate Cox model using Stata data analysis software version 13.1.

**Results**

**Variable selection and RIMARC-based classifiers**

By means of RIMARC algorithm, we obtained the predictive weights ($w$) together with the AUC values of each baseline parameter associated with recurrence of AF in other publications. After applying 10-fold cross-validation on the AUC values produced for each parameter, mean AUC’s with 95% confidence intervals are calculated. Among the initial 21 parameters, 6 variables were identified by the RIMARC algorithm. These variables were heart rate, PC upon flecainide pretreatment, body mass index, left ventricular ejection fraction, baseline SF-12 physical, and mental component scores which indicated as having significant AUC values in determining the primary outcome (Table 1).

**Univariate and multivariate analysis**

The 6 parameters at baseline determined also to have a statistically significant discrimination power via RIMARC were subject to univariate Cox regression analysis and were then used to build a multivariate Cox model. Increased heart rate during AF and PC upon flecainide pretreatment were found to be the significant predictors (significance level, $\alpha = 0.05$) in univariate Cox regression analysis. The results of these analyses are presented in Table 2.

It can be seen that the parameter of pharmacological conversion (PC) upon flecainide pretreatment is the single most relevant predictor of SR maintenance in multivariate Cox regression analysis. The results of these analyses are presented in Table 3. Multivariate Cox regression indicates that successful PC reduced the primary outcome risk by 3.14 times [95% CI: 1.7–5.81] than those with need for electrical cardioversion (hazard ratio: 0.318 [95% CI: 0.172–0.588]; $P < \alpha = 0.05$).

As illustrated in Figure 1, the Flec-SL dataset also shows that while 51% of patients who need electrical cardioversion reach the primary endpoint, this proportion is 23% in those patients who undergo successful PC. Therefore, the dataset also indicates that patients who undergo successful PC are 2.22 ($P < \alpha = 0.05$) times less likely to reach the primary endpoint than those patients who need electrical cardioversion.
The Kaplan–Meier survival analysis of the time-to-primary endpoint also indicates that the mean time-to-primary endpoint of patients who had successful PC is significantly higher than those patients who needed electrical cardioversion. Figure 2 illustrates the survival curves of patients who had successful PC and those who needed electrical cardioversion.

**Discussion**

Using a combination of explorative data mining analyses and confirmation by ‘conventional’ univariate and multivariate Cox hazard proportional models, we identified PC of persistent AF during in-hospital flecainide initiation as an important predictor of longer term maintenance of SR after cardioversion of persistent AF. Patients who were cardioverted back to SR during oral pretreatment with flecainide for 48 h prior to scheduled electrical cardioversion were more than three times as likely to maintain SR for 6 months after cardioversion. Other clinical variables, including duration of AF and atrial size, were not predictive of recurrent AF in this large data set of patients with persistent and long-standing persistent AF.

Several mechanisms cause recurrent AF after cardioversion. In addition to electrical remodelling, structural changes in the atria,

### Table 2 Univariate cox regression analysis

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>SE</th>
<th>Sig. (α = 0.05)</th>
<th>HR</th>
<th>95.0% CI for HR</th>
<th>Lower</th>
<th>Upper</th>
<th>Cases available</th>
<th>Cases censored</th>
<th>Missing values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate</td>
<td>−0.010</td>
<td>0.003</td>
<td>0.001</td>
<td>0.990</td>
<td>0.984</td>
<td>0.996</td>
<td>287</td>
<td>347</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>PC upon flecainide pretreatment</td>
<td>−1.033</td>
<td>0.196</td>
<td>0.000</td>
<td>0.356</td>
<td>0.242</td>
<td>0.523</td>
<td>287</td>
<td>348</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>BMI</td>
<td>0.000</td>
<td>0.012</td>
<td>0.993</td>
<td>1.000</td>
<td>0.976</td>
<td>1.025</td>
<td>284</td>
<td>343</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>0.009</td>
<td>0.008</td>
<td>0.248</td>
<td>1.009</td>
<td>0.994</td>
<td>1.024</td>
<td>233</td>
<td>301</td>
<td>101</td>
<td>0</td>
</tr>
<tr>
<td>SF-12, physical component, baseline</td>
<td>−0.011</td>
<td>0.007</td>
<td>0.095</td>
<td>0.989</td>
<td>0.976</td>
<td>1.002</td>
<td>206</td>
<td>216</td>
<td>213</td>
<td>0</td>
</tr>
<tr>
<td>SF-12, mental component, baseline</td>
<td>0.005</td>
<td>0.007</td>
<td>0.499</td>
<td>1.005</td>
<td>0.991</td>
<td>1.018</td>
<td>205</td>
<td>220</td>
<td>210</td>
<td>0</td>
</tr>
</tbody>
</table>

BMI: body mass index; PC, pharmacological cardioversion.

### Table 3 Multivariate cox regression analysis (full model)

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>SE</th>
<th>Sig. (α = 0.05)</th>
<th>HR</th>
<th>95.0% CI for HR</th>
<th>Lower</th>
<th>Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate</td>
<td>−0.005</td>
<td>0.004</td>
<td>0.269</td>
<td>0.995</td>
<td>0.987</td>
<td>1.004</td>
<td></td>
</tr>
<tr>
<td>PC upon flecainide pretreatment</td>
<td>−1.080</td>
<td>0.278</td>
<td>0.000</td>
<td>0.340</td>
<td>0.197</td>
<td>0.586</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>−0.003</td>
<td>0.016</td>
<td>0.864</td>
<td>0.997</td>
<td>0.966</td>
<td>1.029</td>
<td></td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>0.013</td>
<td>0.009</td>
<td>0.171</td>
<td>1.013</td>
<td>0.995</td>
<td>1.031</td>
<td></td>
</tr>
<tr>
<td>SF-12, physical component, baseline</td>
<td>−0.010</td>
<td>0.008</td>
<td>0.178</td>
<td>0.990</td>
<td>0.975</td>
<td>1.005</td>
<td></td>
</tr>
<tr>
<td>SF-12, mental component, baseline</td>
<td>0.001</td>
<td>0.008</td>
<td>0.925</td>
<td>1.001</td>
<td>0.986</td>
<td>1.016</td>
<td></td>
</tr>
</tbody>
</table>

Cases available in analysis
- Event: 172 / 27.1%
- Censored: 198 / 31.2%
- Total: 370 / 58.3%

Cases dropped
- Cases with missing values: 265 / 41.7%
- Cases with negative time: 0 / 0%
- Censored cases before the earliest event in a stratum: 0 / 0%
- Total: 265 / 41.7%
- Total: 635 / 100.0%

BMI: body mass index; PC, pharmacological cardioversion.

*Dependent variable: time to event (days).
focal firing from the pulmonary veins, and abnormal myocardial calcium handling can cause recurrences.\textsuperscript{10,11} Antiarrhythmic drugs such as flecainide prolong the action potential, increase post-repolarization refractoriness, and increase the curvature of electrical wave fronts in the left atrium, thereby contributing to termination of fibrillatory activity. In addition, flecainide can also prevent focal firing and abnormal intracellular calcium handling.\textsuperscript{8,12}

Pretreatment with flecainide prior to planned electrical cardioversion of AF has not been systematically evaluated before. Although therapeutic antiarrhythmic drug levels immediately after cardioversion can prevent immediate recurrences of AF, pretreatment does not routinely used in common clinical practice. Nonetheless, some observational data sets are available for patients pretreated with amiodarone\textsuperscript{13} and dofetilide\textsuperscript{14}. Galperin et al.\textsuperscript{13} analysed the role of different parameters that determine long-term SR maintenance in patients with persistent AF who are treated with amiodarone. They enrolled 141 anticoagulated patients with persistent AF who were pretreated for 4 weeks with oral amiodarone. Those in whom the arrhythmia persisted underwent electric cardioversion. After restoration of normal SR (either pharmacologic or electric), all patients received a daily dose of amiodarone and were followed $\approx$2 years. Concordant with our findings, PC during pretreatment was one of the major determinants for long-term SR maintenance.\textsuperscript{13}

Malhotra et al.\textsuperscript{14} retrospectively reviewed elective inpatient admissions for dofetilide loading. They used a multivariate Cox proportional hazards model to assess predictors of maintenance of SR after in-hospital dofetilide loading. They found that patients who converted pharmacologically upon dofetilide pretreatment remained longer in SR compared with the patients who required electrical cardioversion.\textsuperscript{14} Thus, our main finding is in line with other reports on other antiarrhythmic drugs.

\begin{table}
\begin{tabular}{|l|l|}
\hline
PC upon flecainide pretreatment & \text{Mean} \pm \text{SE} \\
\hline
NO & 106.941 \pm 4.047 \\
YES & 161.149 \pm 6.239 \\
Overall & 117.787 \pm 3.578 \\
\hline
\end{tabular}
\end{table}
Recent epicardial mapping data suggest that the electrical complexity of AF differs markedly between patients with persistent AF.\textsuperscript{15,16} Although we cannot provide definitive proof for this hypothesis, it is possible that PC of persistent AF during flecainide pretreatment could be a marker for low complexity of AF.\textsuperscript{17,18} Furthermore, it is conceivable that PC of AF identifies a group of patients who are responsive to therapy with flecainide which was given to the majority of patients during follow-up.\textsuperscript{2}

The main reason why RIMARC was selected as the data mining algorithm of choice is the proven accuracy and performance of RIMARC algorithm, and that it yields easily interpretable and clinically relevant results. The predictive performance of RIMARC algorithm over a wide range of commonly used data mining algorithms with 10 benchmark data sets was shown in comparative experiments.\textsuperscript{5} The comparison is made on the AUC metric owing to the fact that it is a widely accepted in evaluating the accuracy of a classification performance. Valid arguments were theoretically and empirically supplied as to why AUC should be preferred over accuracy, which is merely a ratio of correctly predicted results to the total number of instances examined.\textsuperscript{19,20} A higher value of AUC for a parameter is an indication of its higher relevance in determining the class label. Since RIMARC algorithm aims to maximize the AUC value directly, it outperforms the other data mining algorithms on average, with a statistically significant difference.\textsuperscript{5–7}

Furthermore, RIMARC has several advantages compared with other algorithms of medical data mining and decision support, which can be summarized as follows:

(i) RIMARC is a non-parametric machine learning method, thus no parameter tuning is needed to attain an optimal classifier.

(ii) RIMARC is highly robust to the frequently encountered ‘missing value’ problem in clinical datasets.

(iii) RIMARC’s main output is a human-readable, intuitive ‘ranking function’ that lists the order of influence of input variables and their impacts (i.e.‘weights’) on the ranking function.

(iv) The impacts of individual input variables on the ranking function are calculated independently. Therefore, any addition or removal of variables does not affect the individual weights of the input variables in the classifier.\textsuperscript{5,6}

Conclusion and clinical perspective
This analysis of the Flec SL-AFNET 3 data set using both data mining and classical statistical methods suggests that PC during 48 h of oral therapy of persistent AF patients with flecainide is a powerful and independent predictor of maintenance of SR after cardioversion. Based on these findings, some additional insight into the durability of SR after cardioversion and AF treatment is obtained. Collection of further data is needed to establish and plan subsequent steps in short-term, long-term antiarrhythmic drug treatment and prevent recurrent AF after cardioversion. Acknowledging the hypothesis-generating nature of our analysis, oral pretreatment with antiarrhythmic drugs seems a reasonable and simple intervention prior to cardioversion that can help to identify patients at low risk of recurrent AF.

Limitations

The present analysis is a retrospective analysis of the Flec SL—AFNET 3 data set. The data set provides information on a large contemporary cohort of patients undergoing cardioversion of AF. In addition, the data mining used, where the hypothesis is not pre-specified, and the study is initially hypothesis free. As any retrospective analysis, it is hypothesis generating. This is a large cohort of patients, many of whom have long-standing AF (mean duration 28 months), therefore spontaneous conversions occurred in ~20% of patients.

Funding

This work was supported by European Union through EUTRAF (FP7, to P.K., A.G., and A.O.) and under grant agreement No 633193 (CATCH ME, to P.K.), by British Heart Foundation (FS/13/32/30324, to P.K.), by the German Ministry of Education and Research through AFNET (01GI0204, to G.B., U.R., A.G., P.K.) and through funds from the German Centre for Cardiovascular Research (DZHK, to P.K. and G.B.). Additional funds for the conduct of the Flec SL—AFNET 3 trial were provided by MEDA Pharma.

Conflict of interest

none declared.

References


